US Patent 6,730,325: Scope of Claims, Claim Construction Touchpoints, and US Patent Landscape
US Patent 6,730,325 claims a multiparticulate, modified-release oral composition that produces pulsatile delivery of a central nervous system (CNS)-acting drug by combining (i) a first particle population and (ii) a subsequent particle population having a modified-release coating or matrix. The independent claim is built around the sequencing concept: the first population releases first, and the subsequent population releases later to generate a “pulse.”
What is the core invention in claim 1?
Claim 1 defines the invention’s boundary conditions:
Claim 1 elements (minimum required scope)
- Multiparticulate modified release composition
- First population of active ingredient-containing particles
- At least one subsequent population of active ingredient-containing particles
- The active ingredient in the first population is a drug compound that acts on the CNS
- The subsequent population comprises either:
- modified release coating, or
- modified release matrix material, or
- both (alternative or additional)
- After oral delivery, the composition delivers active ingredients in a pulsatile manner for the first and subsequent populations
Key scope levers embedded in claim 1
- “Multiparticulate”: pushes scope toward pellets/mini-tablets/multiparticulate drug cores rather than monolithic tablets (though later dependent claims expressly broaden dosage forms).
- “First and subsequent populations”: requires at least two populations with different release functions/timing.
- “CNS acting”: functional limitation that can cover multiple CNS indications and multiple drug classes, not only ADHD stimulants.
- “Pulsatile manner”: a performance requirement tied to oral delivery, not just structural feature.
How do dependent claims narrow or expand the scope?
Population structure and release modality
- Claim 2: composition has one subsequent population (limits to two populations total).
- Claim 3: first population is immediate-release (IR); subsequent population is modified-release (MR).
- Claims 4 and 5: subsequent population MR particles are:
- coated (claim 4), or
- matrix (claim 5)
Claim 12 mirrors the same structure: first population particles are IR, subsequent are MR.
Release sequencing requirement
- Claim 13: first population releases substantially all of the active ingredient prior to release from the subsequent population.
This “substantially all” sequencing phrase materially narrows enforcement arguments: infringers that allow meaningful overlap between the two populations can attack literal infringement, depending on claim construction.
Release mimicry (in vivo pacing)
- Claim 14: in vivo release from the first/subsequent populations mimics in vivo release of the same active ingredient administered as two or more doses of IR forms.
This can expand interpretive scope toward objective pharmacokinetic shape matching, not necessarily identical time points.
Dissolution timing window
- Claim 15: mean in vitro dissolution in aqueous medium: substantially all active ingredient from the first population releases within about two hours.
This provides a testable parameter that can support both prosecution and infringement positions.
Which CNS drugs are explicitly covered?
The claim set uses a broad CNS functional anchor in claim 1, then explicitly enumerates methylphenidate as a preferred CNS stimulant.
Specific stimulant selection
- Claim 6: first population contains a cerebral stimulant
- Claim 7: that stimulant is methylphenidate (or pharmaceutically acceptable salt), and covers:
- enantiomers,
- racemate,
- mixtures.
So the patent’s commercial target is clearly the methylphenidate family, but claim 1’s CNS function can still cover other CNS-acting compounds if the rest of the multiparticulate pulsatile architecture is met.
How does the patent define “pulsatile” in mechanistic terms?
Claim 1 uses a functional performance outcome: pulsatile manner. Dependent claims supply more explicit mechanistic embodiments.
Pulse-by-delay via pH-dependent polymer coating
- Claim 25: MR particles use a pH-dependent polymer coating effective to release a pulse after a time delay.
- Claim 26: coating comprises methacrylate copolymers.
- Claim 27: coating comprises methacrylate + ammonio methacrylate copolymers in a ratio sufficient for pulse after delay.
- Claim 28: ratio methacrylate : ammonio methacrylate = 1:1
These dependent claims tighten scope toward a particular polymer system and a specific mixture ratio, which can be used as a “design-around map” for competitors who change the polymer type or ratio.
What other formulation variants are claimed?
Additional actives
- Claim 8: composition contains at least one additional active ingredient.
This can enlarge the claims’ coverage in combination formulations.
Enhancers
- Claim 9: either the first or subsequent populations can further include an enhancer.
“Enhancer” is broad and can include permeability enhancers, absorption modifiers, or other excipients depending on claim interpretation.
Dose amount range
- Claim 10: each population active amount is about 0.1 mg to about 1 g.
This is a wide numeric range intended to cover practical dosing and prevent narrow carveouts.
Different dissolution profiles
- Claim 11: first and subsequent populations have different in vitro dissolution profiles.
This supports argument that the formulation must be engineered with distinct release kinetics.
Dosage forms: beyond multiparticulate blends
The claims cover multiple dosage architectures for delivering the same two-population concept.
Capsules
- Claim 16: dosage form comprising composition of claim 1
- Claim 19: capsule contains blend of particles from each population in:
- hard gelatin or soft gelatin
- Claim 20: particles of each population are mini-tablets, capsule contains mixture of mini-tablets.
Compressed tablets
- Claim 21: multilayer tablet with:
- first layer = compressed particles of first population
- another layer = compressed particles of subsequent population
This can create a path to literal infringement by a layered tablet even if the physical particles are compressed, assuming the layers still embody the claim’s population concept.
Rapidly dissolving dosage forms
- Claim 22: first and subsequent populations are provided in a rapidly dissolving dosage form
- Claim 23: form is a fast-melt tablet
This is a meaningful scope extension because it can move the concept into orally disintegrating platforms while preserving the multiparticulate two-population pulse mechanism.
Methods of use scope
- Claim 24: method for treatment of attention deficit disorder by administering therapeutically effective amount of the composition of claim 7.
This locks the method claims to methylphenidate embodiments and ADHD treatment.
What does the claim set imply about the likely infringement map?
Literal infringement is likely driven by these features
- Two populations (IR first, MR second) with separate active-containing particles
- MR mechanism: coating or matrix producing delayed pulse
- Sequencing: first population releases substantially all before the second begins
- Performance: pulsatile oral delivery outcome; dissolution and timing parameters in dependent claims
Common design-around pressure points
- Replace IR first population with non-IR release profile (attacks claim 3/12)
- Allow partial overlap between first and second release (attacks claim 13 “substantially all” sequencing)
- Use MR mechanism not covered by coating/matrix construction (attacks claims 4/5 and 25)
- Swap away from pH-dependent methacrylate/ammonio methacrylate polymer coating systems (attacks claims 25-28)
How broad is the protection relative to the methylphenidate pulsatile market?
From the claim structure, the patent provides:
- Breadth at claim 1: CNS-acting drug + two population pulsatile architecture (coating or matrix).
- Commercial specificity via methylphenidate: claim 7 and ADHD method claim 24.
- Additional specificity in embodiments: fast-melt, capsule mini-tablets, multilayer tablets, pH-dependent methacrylate/ammonio methacrylate polymer coatings.
In practical landscape terms, this is a “platform-to-ingredient” blend: competitors must consider both architecture and drug identity.
US patent landscape construction (what to look for around US 6,730,325)
Without reproducing an exhaustive bibliography of all US filings in the space (which would require full bibliographic and assignment retrieval), the enforcement and freedom-to-operate analysis for this patent is built around three patent families that typically surround methylphenidate multiparticulate pulsatile systems:
1) IR + delayed MR methylphenidate dosage forms
Targets:
- multiparticulates
- distinct IR and MR populations
- delayed “second peak” behavior in vivo
Why it matters for US 6,730,325: claim 1 and claims 3/12/13/14 anchor on exactly this sequence and pulse mimicry. Prior art in this area usually attacks either:
- the two-population concept, or
- the “pulsatile” performance articulation.
2) Polymer-controlled delayed release coatings (especially pH-dependent methacrylates)
Targets:
- pH-triggered dissolution/erosion
- methacrylate-type copolymer blends
- time delay before pulse release
Why it matters: claims 25-28 are narrow and likely to be the most vulnerable to prior art if earlier filings disclose the same polymer system and ratio logic.
3) Multiparticulate implementation in specific dosage formats
Targets:
- capsules containing blends of IR and MR mini-tablets
- multilayer tablets with discrete compressed layers
- fast-melt/rapidly dissolving platforms
Why it matters: claims 19-23 can be the hook for enforceability against specific product forms even when the underlying two-population mechanics are present.
Claim-to-landscape mapping: where competitors can face risk
High-risk overlap zones
- Products that use two populations where the first is effectively immediate release and the second produces a delayed pulse
- Formulations that use pH-dependent methacrylate/ammonio methacrylate coatings or close equivalents
- Products targeting ADHD with methylphenidate where the dosing profile is designed to mimic multiple IR doses
Lower-risk zones (potential design avoidance)
- Single-population systems (no subsequent distinct population)
- MR where release does not occur as a distinct pulse after delay
- Non-methacrylate MR systems or non-pH-triggered coatings
- Architectures that do not satisfy the “substantially all” sequential release window (for the first population)
Key Takeaways
- US 6,730,325 protects a two-population multiparticulate oral system that produces pulsatile delivery by pairing an IR first population (explicit in claims 3/12) with a delayed MR second population (coating or matrix).
- The invention is broad at claim 1 for CNS-acting drugs, but commercially focused via claims 6-7 and the ADHD method claim 24 on methylphenidate.
- Dependent claims 25-28 narrow to pH-dependent polymer coatings using methacrylate copolymers, including a specific methacrylate : ammonio methacrylate = 1:1 ratio embodiment.
- The strongest practical enforcement criteria are the sequencing requirement (substantially all release from the first population before the second) and the in vitro/in vivo timing constructs (claims 13-15 and 14).
- The dosage-form claims expand implementation risk across capsules (mini-tablet blends), multilayer tablets, and fast-melt rapidly dissolving dosage forms.
FAQs
1) Does claim 1 require methylphenidate?
No. Claim 1 requires only that the first population active ingredient is a CNS-acting drug. Methylphenidate is specified in claim 7, with an ADHD use method in claim 24.
2) Is a coating required for infringement?
Not for claim 1. Claim 1 allows the subsequent population to have a modified release coating or a modified release matrix (or both). Coating-only is specifically required in claim 4; matrix-only is specified in claim 5.
3) What makes the pulse requirement legally actionable?
Claim 1 states pulsatile delivery as an outcome, and dependent claims add testable anchors like release sequencing (claim 13), dissolution timing (claim 15), and in vivo mimicry of multiple IR doses (claim 14).
4) How narrow are the polymer claims?
Claims 25-28 are narrow embodiments requiring pH-dependent coating and specifying methacrylate copolymers, including a specific ammonio methacrylate mixture ratio.
5) Do the dosage-form claims matter if the formulation is correct?
Yes for product infringement strategy. Claims 19-23 cover specific packaging/format implementations (hard/soft gelatin capsules with mini-tablets, multilayer tablets, and fast-melt rapidly dissolving forms), which can matter for enforcement against marketed presentations.
References
[1] US Patent 6,730,325 (claims as provided).
